Determination of cGMP levels in rodent tissues following oral dosing of a soluble guanylate cyclase stimulator
© Perez et al; licensee BioMed Central Ltd. 2013
Published: 29 August 2013
The current study shows that our sGC stimulators are able to increase cGMP levels in both the rat aorta and pulmonary vein and indicates the potential for sGC stimulators to act as balanced vasodilators.
- Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, Burnett JC: Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation. 2003, 107: 686-9. 10.1161/01.CIR.0000055737.15443.F8.View ArticlePubMedGoogle Scholar
- Mitrovic V, Swidnicki B, Ghofrani A, Mück W, Kirschbaum N, Mittendorf J, Stasch JP, Wensing G, Reiner Frey R, Lentini S: Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. BMC Pharmacology. 2009, 9 (Suppl 1): P51-10.1186/1471-2210-9-S1-P51.PubMed CentralView ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.